Bruno P. Imbimbo

Parma, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 144 publications

[18F]-florzolotau PET imaging in Alzheimer's disease: Current evidence and future directions.

[18F]-florzolotau PET imaging in Alzheimer's disease: Current evidence and future directions.

Journal: Journal of Alzheimer's disease : JAD
Published: July 28, 2026

Sex-specific associations between astrocytic reactivity and cognitive decline in unimpaired elderly.

Sex-specific associations between astrocytic reactivity and cognitive decline in unimpaired elderly.

Journal: bioRxiv : the preprint server for biology
Published: July 10, 2026

Frailty as an underrepresented dimension in clinical trials of Alzheimer's disease therapies.

Frailty as an underrepresented dimension in clinical trials of Alzheimer's disease therapies.

Journal: Journal of Alzheimer's disease : JAD
Published: July 09, 2026

Reply: The disconnectome as target in Alzheimer disease: a promising framework or a premature end-point?

Reply: The disconnectome as target in Alzheimer disease: a promising framework or a premature end-point?

Journal: Brain : a journal of neurology
Published: June 29, 2026

CHF6467 Exerts Neuroprotective Effects in the Rat Model of Acute Ischemic Stroke.

CHF6467 Exerts Neuroprotective Effects in the Rat Model of Acute Ischemic Stroke.

Journal: Brain sciences
Published: June 26, 2026

Physical Exercise and Gut Microbiota: Implications for Alzheimer's Disease in Experimental Models: A Systematic Review and Meta-Analysis.

Physical Exercise and Gut Microbiota: Implications for Alzheimer's Disease in Experimental Models: A Systematic Review and Meta-Analysis.

Journal: Journal of functional morphology and kinesiology
Published: June 15, 2026

Number needed to treat and harm for lecanemab and donanemab in early Alzheimer disease.

Number needed to treat and harm for lecanemab and donanemab in early Alzheimer disease.

Journal: Journal of neurology
Published: April 24, 2026

GLP-1 receptor agonists at the crossroads of obesity and addiction: A review of shared neurobiology and translational evidence.

GLP-1 receptor agonists at the crossroads of obesity and addiction: A review of shared neurobiology and translational evidence.

Journal: Pharmacology, biochemistry, and behavior
Published: April 06, 2026

Comparison of double-blind and open-label decline rates in lecanemab and donanemab trials in Alzheimer's disease.

Comparison of double-blind and open-label decline rates in lecanemab and donanemab trials in Alzheimer's disease.

Journal: BMJ neurology open
Published: March 31, 2026

Long-term treatment of early Alzheimer's disease with donanemab.

Long-term treatment of early Alzheimer's disease with donanemab.

Journal: The journal of prevention of Alzheimer's disease
Published: February 04, 2026

Revisiting the cognitive potential of lithium in alzheimer's disease: the role of cholinergic system and brain connectivity.

Revisiting the cognitive potential of lithium in alzheimer's disease: the role of cholinergic system and brain connectivity.

Journal: Translational psychiatry
Published: January 20, 2026

Comparing clinical effect sizes of SouvenaidTM, lecanemab, and donanemab in early Alzheimer's disease.

Comparing clinical effect sizes of SouvenaidTM, lecanemab, and donanemab in early Alzheimer's disease.

Journal: Journal of Alzheimer's disease : JAD
Published: December 22, 2025
Showing 1-12 of 144

Last Updated: 09/26/2026